Faron Pharmaceuticals - Innovative medical solutions (Part 2)

[Critter1]

@ValkoinenPeura

However, it is quite typical that primary subscriptions are not fully subscribed. In Faron’s case, the essential thing in my opinion is whether any shares were left for the underwriters after the secondary subscriptions.

A few were left, 52% of the shares were subscribed. A successful offering, as Faron announced.